Disease Epidemiology Collaboration] equation), or missing PTH value. "Loop users" had prescriptions for furosemide, bumetanide, or torsemide.
Baseline characteristics of loop users and nonusers were compared using t tests or χ 2 tests. A multivariable linear regression model was constructed to test the association between loop use and natural log-transformed PTH level. Covariates were age, sex, body mass index (BMI), history of congestive heart failure (CHF); smoking; dietary calcium and phosphorus intake; eGFR; and levels of serum 25-(OH) vitamin D, calcium, phosphorus, uric acid, albumin, and alkaline phosphatase. Least-square means were used to estimate natural log-transformed PTH levels of loop users and nonusers. These values were exponentiated and the adjusted geometric means of PTH level from the final model are reported. Multivariable logistic regression was used to test the association between loop use and odds of a PTH level higher than 65 pg/mL.
Results | Of 20 470 participants, 9287 were younger than 18 years; 2217 had an eGFR lower than 60 mL/min/1.73 m 2 , and 3
were missing a PTH value. The remaining 8963 participants were included in the analysis. After application of survey weights, 1.8% of participants were loop users. Loop users were more likely to be female, older, nonsmokers, and have a higher BMI (Table) . They had significantly higher uric acid and alkaline phosphatase levels but lower eGFR, 25-(OH) vitamin D, and albumin levels. Loop users had a lower dietary intake of calcium and phosphorus and were more likely to have a history of CHF. Race and serum calcium and phosphorus levels were similar between groups.
The Figure depicts the range of PTH levels among loop users and nonusers. Using the final multivariable model, the adjusted geometric mean PTH level in loop users was significantly higher than in nonusers (43.4 pg/mL compared with 38.8 Discussion | Our results demonstrate that loop use associates with higher PTH, even after adjustment for potential confounders. While previous studies have found similar associations in CKD, we demonstrate that this relationship extends to patients with preserved kidney function, having an impact on a considerably larger population. Clinicians often monitor for electrolyte changes after initiation of loop diuretics but may not measure PTH level. Many loop users are elderly or have CHF, both of which contribute to bone loss. Use of a different diuretic class, repletion of vitamin D, or increased dietary calcium intake may combat a rise in PTH and reduce the risk of adverse outcomes.
Conclusions | This study included a large, representative sample of adults. Many variables known to influence PTH level were included in the analysis. Missing data limited our ability to examine the relationship between loop use and clinical outcomes, and while we tried to control for potential confounders, residual confounding may exist. Prospective studies are needed to define the direct effect of loop use on PTH level. Nonetheless, our work suggests that loop diuretic use may lead to elevation in PTH level and consequently other adverse clinical effects.
Eligibility for Statin Therapy According to New Cholesterol Guidelines and Prevalent Use of Medication to Lower Lipid Levels in an Older US Cohort: The Atherosclerosis Risk in Communities Study Cohort
The 2013 guidelines of the American College of Cardiology and American Heart Association (ACC/AHA) for treatment of cholesterol levels recommend statin therapy for individuals at an elevated absolute risk for cardiovascular disease (CVD). 1 This risk-based approach is a paradigm shift from prior Adult Treatment Panel (ATP) III guidelines 2 that were influenced heavily by thresholds for low-density lipoprotein cholesterol levels. A recent analysis estimated that the ACC/AHA guidelines will lead to a significant increase in statin use in the United States, largely owing to an increase in the eligibility of adults older than 60 years without CVD or diabetes mellitus. 3 The effect of the new guidelines on older individuals is important because they are at high risk for CVD but also may be prone to the adverse effects of statin use. 4 The aim of this 
